Skip to main content
Clinical Trials/NCT04364880
NCT04364880
Completed
Not Applicable

Neuropsychobiology of Brain Theta-burst Stimulation: A Mind-body Interface for Depression

National Science Council, Taiwan0 sites80 target enrollmentJanuary 1, 2012

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Depression
Sponsor
National Science Council, Taiwan
Enrollment
80
Primary Endpoint
Hamilton Rating Scale for Depression (HAMD)
Status
Completed
Last Updated
3 years ago

Overview

Brief Summary

This is a sham-controlled, randomized trial for patients with MDD to identify the effects of TBS on depressive symptomatology, brain function, and peripheral biomarkers in MDD patients.

Detailed Description

This is a sham-controlled, randomized trial for patients with MDD to identify the effects of TBS on depressive symptomatology, brain function (e.g. functional MRI, PET, and qEEG), peripheral biomarkers (e.g. candidate genetic expression, neuroendocrine, inflammation, and neurotransmissions) in MDD patients.

Registry
clinicaltrials.gov
Start Date
January 1, 2012
End Date
December 31, 2015
Last Updated
3 years ago
Study Type
Interventional
Study Design
Parallel
Sex
All

Investigators

Sponsor
National Science Council, Taiwan
Responsible Party
Principal Investigator
Principal Investigator

Kuan-Pin

China Medical University Hospital

National Science Council, Taiwan

Eligibility Criteria

Inclusion Criteria

  • The diagnostic criteria of DSM-IV for MDD
  • The range of the age from 18 to 70-year-old
  • Physically healthy on medical history, physical examination, and laboratory parameters within normal limits
  • Competent for a full explanation of the study and written informed consent is obtained.

Exclusion Criteria

  • Having other current Axis I disorders (except nicotine dependence), patients with psychotic disorders, bipolar disorders, organic mental disorders, and a prevailing strong suicidal risk were excluded
  • History or family history of seizure disorder
  • Known neurological disorders or evidence of central nervous system disease based on baseline complete neurological examination, electroencephalography, and magnetic resonance imaging of the brain
  • Having ferromagnetic material in the body or close to the head (implanted pacemaker or medication pump, metal plate in skull, or metal objects in the eye or skull)

Outcomes

Primary Outcomes

Hamilton Rating Scale for Depression (HAMD)

Time Frame: From Weeks 0 to 24

The Hamilton Depression scale sum score (HAMD21) * Not depressed: 0-7 * Mild: 8-13 * Moderate: 14-18 * Severe: 19-22 * Very severe: \>23

Secondary Outcomes

  • Response rate(From Weeks 0 to 24)
  • Remission rate(From Weeks 0 to 24)

Similar Trials